Send the following on WhatsApp
Continue to Chathttps://business24.ch/2023/02/22/karyopharm-und-menarini-group-erhalten-vollstaendige-zulassung-der-mhra-fuer-nexpovio-selinexor-in-kombination-mit-bortezomib-und-dexamethason-zur-behandlung-von-erwachsenen-patienten-mit-mult/